HER-2 Protein AutoVac: Phase II discontinued

PHARMX stopped a Phase II trial of its HER-2 Protein AutoVac breast cancer vaccine with QS-21 adjuvant because the first 10 patients' disease progressed during the study. Also, the preliminary data su...